Initiation factor eIF2B not p70 S6 kinase is involved in the activation of the PI-3K signalling pathway induced by the v-src oncogene  by Vojtěchová, Martina et al.
Initiation factor eIF2B not p70 S6 kinase is involved in the activation of
the PI-3K signalling pathway induced by the v-src oncogene
Martina Vojte›chova¤, Eva S)loncova¤, Dana Kuc›erova¤, Jaroslav Jir›ic›ka, Vlasta Sovova¤,
Zdena Tuha¤c›kova¤
Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 16637 Prague 6, Czech Republic
Received 5 March 2003; revised 17 April 2003; accepted 17 April 2003
First published online 1 May 2003
Edited by Lev Kisselev
Abstract Our data show that in hamster ¢broblasts trans-
formed by Rous sarcoma virus (RSV), the phosphoinositide
3P-kinase (PI-3K)/Akt/glycogen synthase kinase 3 antiapoptotic
pathway is upregulated and involved in increased protein syn-
thesis through activation of initiation factor eIF2B. Upon inhi-
bition of PI-3K by wortmannin, phosphorylation of 70-kDa ri-
bosomal protein S6 kinase (p70 S6k) and its physiological
substrate, ribosomal protein S6, decreased in the non-trans-
formed cells but not in RSV-transformed cells. Thus PI-3K,
which is thought to be involved in regulation of p70 S6k, signals
to p70 S6k in normal ¢broblasts, but it does not appear to be an
upstream e¡ector of p70 S6k in ¢broblasts transformed by v-src
oncogene, suggesting that changes in the PI-3K signalling path-
way upstream of p70 S6k are induced by RSV transformation.
1 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Several proteins which undergo control in mammalian
translational machinery are targets of the mammalian target
of rapamycin (mTOR). Among them is the 70-kDa ribosomal
protein S6 kinase (p70 S6k) that catalyzes phosphorylation of
the 40S ribosomal protein S6. Activation of p70 S6k leads to
the upregulation of protein biosynthesis and increases the
translational capacity of the cell by stimulation of the selective
translation of 5P-TOP (terminal oligopyrimidine tract)
mRNAs that primarily encode proteins and components of
the translational apparatus. Recruitment of these mRNAs to
translating polysomes may be the mechanism by which p70
S6k regulates cell growth [1].
Expression of a speci¢c subset of mRNAs that possess long
highly structured 5P-untranslated regions is also regulated at
the level of translation initiation by rapamycin-sensitive mech-
anisms. Rapamycin inhibits cap-dependent translation prob-
ably by blocking the function of the cap-binding protein
eIF4E which is regulated by the translation repressor proteins
(4E-BP1,2) [2]. By controlling cap-dependent translation and
the translation of 5P-TOP mRNA, the mTOR signalling path-
way upregulates the translational machinery under favorable
growth conditions [3].
Another important signalling pathway that is activated by
growth-promoting stimuli is the rapamycin-insensitive path-
way which involves phosphoinositide 3P-kinase (PI-3K). This
pathway is inhibited by wortmannin, a selective inhibitor of
PI-3K. Activation of the PI-3K pathway is initiated by an
increased level of speci¢c 3-phosphoinositides (3-PtdIns) that
are generated by the activated PI-3K. Interactions of these
lipids with the lipid-binding ‘pleckstrin homology’ (PH) do-
mains present in some proteins leads to the activation of ser-
ine/threonine protein kinases including 3P-phosphoinositide-
dependent protein kinase 1, protein kinase B (PKB/Akt) and
p70 S6k, and inactivation of glycogen synthase kinase 3
(GSK-3) [4]. Nevertheless, the regulation of p70 S6k involving
inputs from signalling events linked to PI-3K is not yet fully
understood. Recent work suggests that this may involve the
components of the tuberous sclerosis complex TSC1 and
TSC2, TSC2 being a direct substrate for Akt [5].
Since the activated protein product of the src gene is in-
volved in multiple mechanisms by which cells are transformed
into the malignant phenotype, we analyzed cells that were
transformed by Rous sarcoma virus (RSV) to explore the
mechanisms that control mRNA translation and may be in-
volved in the process of cell malignant transformation induced
by the v-src oncogene. Signi¢cantly higher amounts of the
activated Src protein are present in RSV-transformed ¢bro-
blasts compared to non-transformed hamster ¢broblasts [6].
The enhanced expression of Src correlated with increased lev-
els of overall protein synthesis in these cells and, upon rapa-
mycin treatment, both synthesis of Src and global protein
synthesis were less suppressed in RSV-transformed cells rela-
tive to control cells, indicating that some other rapamycin-
insensitive regulatory mechanisms are activated in hamster
¢broblasts by their RSV transformation [7]. To identify such
regulatory mechanisms, we analyzed PI-3K signalling and
found that the PI-3K signalling pathway di¡erentially con-
trols translation in normal and RSV-transformed hamster ¢-
broblasts.
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2. Materials and methods
2.1. Materials
[Q-32P]ATP (3000 Ci/mmol), [35S]methionine/cysteine (Promix),
[3H]GDP (11.9 Ci/mmol), second antibody (anti-rabbit Ig and anti-
mouse Ig), glutathione-Sepharose 4B and ECL Western blotting de-
tection kits were from Amersham, UK. Wortmannin, rapamycin and
all general reagents were obtained from Sigma (USA), unless other-
wise stated. Microcystin LR was from Calbiochem (USA) and TLC
plates SilicaGel-Kieselgur were obtained from Merck (Germany).
Polyclonal antibody anti-p70 S6k, monoclonal anti-phosphotyrosine
antibody PY 99 and anti-4E-BP1 antibody were obtained from Santa
Cruz Biotechnology (USA). Monoclonal anti-Src antibody LA 074
were from Quality Biotech (USA). Polyclonal antibodies anti-Akt,
anti-phospho-Akt(Ser473), anti-phospho-S6 ribosomal protein(S-
er235/236) and the GSK-3 fusion protein were from Cell Signalling
Technology (USA) and anti-GSK-3L antibody was obtained from
Transduction Laboratories.
2.2. Cell culture and preparation of cell extracts
The hamster tumor cell line H19 and the control hamster embryo
cell line NIL-2 were grown as described in [7]. Cells were incubated
with rapamycin as described [7] or incubated with wortmannin added
to a ¢nal concentration of 100 nM (dimethyl sulfoxide (DMSO) so-
lution diluted in medium 1U106) for 10 min or with DMSO carrier
alone for 10 min, unless otherwise indicated. The cells were then lysed
in ice-cold extraction bu¡er A (40 mM L-glycerophosphate, 100 mM
HEPES pH 7.4, 5 mM EGTA, 50 mM NaF, 5 mM Na4P2O7, 1 mM
Na3VO4, 1 mM benzamidine, 0.5 mM phenylmethylsulfonyl £uoride
(PMSF), 1% Triton X-100, 0.05 WM microcystin and the proteinase
inhibitors pepstatin, antipain and leupeptin (0.04 Wg/ml each)) unless
otherwise indicated. Measurement of protein synthesis was performed
as described previously [7] with the exception that the cells were met-
abolically labelled in a medium containing [35S]methionine/cysteine
(100 WCi/ml), and wortmannin (100 nM ¢nal concentration in me-
dium) instead of rapamycin, was used. To determine the expression
of the Src protein, the extracts of the labelled cells (0.5 mg) that were
non-treated or treated with 100 nM wortmannin for 20 h were im-
munoprecipitated, subjected to electrophoresis followed by immuno-
blotting and radioactivity associated with the protein band corre-
sponding to Src was measured as described in [7].
2.3. Immunoprecipitation of proteins
Proteins (0.6 mg) were immunoprecipitated from the cell extract by
incubation for 2 h at 4‡C either with speci¢c monoclonal antibodies
preadsorbed to 10 Wl protein G-Sepharose or with speci¢c polyclonal
antibodies preadsorbed to 2.5 mg protein A-Sepharose. Immune com-
plexes were washed with ice-cold extraction bu¡er and the proteins
were either eluted from the beads by boiling in electrophoresis sample
bu¡er or resuspended in 50 mM Tris^HCl pH 7.5 to a ¢nal volume of
10 Wl.
2.4. Protein kinase assays
2.4.1. PKB/Akt activity. Peptide and protein phosphorylation as-
says of PKB/Akt activity were performed in a ¢nal volume of 20 Wl as
described in [8]. For the RPRAATF peptide phosphorylation assay,
the reaction mixture (20 Wl) was spotted onto P81 ¢lter paper followed
by several washes with 75 mM phosphoric acid and the radioactivity
associated with the dried ¢lters was counted by liquid scintillation
spectrometry. When the protein substrate GSK-3 was used, incuba-
tion of the reaction mixtures was terminated by the addition of elec-
trophoretic sample bu¡er and the samples were subjected to sodium
dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE).
Gels were then stained, washed in neutral solution, dried and auto-
radiographed as in [9].
2.4.2. GSK-3 activity. The assay was carried out in 25 Wl ¢nal
volume of the mixture containing 50 mM Tris^HCl pH 7.5, 10 Wl
immunoprecipitate, 50 WM substrate peptide RRAAEELDS-
RAGpSPQ [10,11], 1 mM dithiothreitol (DTT), 10 mM MgCl2,
100 WM ATP and 2 WCi [Q-32P]ATP. The mixtures were incubated
for 7 min at 30‡C. 20 Wl of the reaction mixtures were spotted on
P81 ¢lters and treated as described above.
2.5. Thin layer chromatography (TLC) of the PI-3K lipid products
Cells were extracted in lysis bu¡er containing 1% Triton X-100, 40
mM L-glycerophosphate, 5 mM DTT. Protein extract (2 mg) was
immunoprecipitated overnight at 4‡C with 10 Wl anti-phosphotyrosine
antibody. Phosphatidylinositol was dispersed by sonication in a bu¡er
containing 20 mM Tris^HCl pH 7.5, 1 mM EDTA and 5 mM DTT
and the immunoprecipitates were preincubated with the lipid solution
at room temperature for 10 min. The reaction mixture (50 Wl) con-
tained 20 mM Tris^HCl pH 7.5, 1 mM EDTA, 5 mM DTT, 10 mM
MgCl2, 25 Wg of phosphatidylinositol, 100 WM ATP and 2 WCi [Q-
32P]ATP. The reaction was carried out for 10 min at 37‡C and termi-
nated by the addition of 200 Wl 1 N HCl, 80 Wl methanol and 80 Wl
chloroform. After centrifugation, the upper phase was removed and
the chloroform phase was washed twice with 200 Wl mixture contain-
ing 1 N HCl:methanol (1:1). 30 Wl of the chloroform extract was
spotted on an oxalate-treated SilicaGel-Kieselgur TLC plate that
was developed in a mobile phase of n-propanol:2 M acetic acid
(65:35) [12], air-dried and quanti¢ed by InstantImager autoradiogra-
phy (Packard).
2.6. Initiation factors eIF2 and eIF2B
For analysis of initiation factors eIF2B and eIF2, lysis bu¡er G (50
mM HEPES pH 7.4, 0.2 mM EGTA, 0.2 mM EDTA, 10% glycerol
(v/v), 1% Triton X-100, 0.2 mM benzamidine, 100 mM KCl, 0.5 mM
PMSF, 1 WM microcystin, pepstatin, antipain and leupeptin (0.4 Wg/
ml each), 1 mM DTT) was used. eIF2 was puri¢ed from hamster
¢broblasts NIL-2 principally as described in [13]. The phosphoryla-
tion state of eIF2K was examined by isoelectric focusing of the par-
tially puri¢ed eIF2K as described [14].
2.7. eIF2B activity measurement
A binary complex eIF2^[3H]GDP was formed as described [15].
Brie£y, 1 pmol eIF2 was incubated with 0.5 WM [3H]GDP in 20 mM
Tris^HCl, pH 7.6, 100 mM KCl, 1% bovine serum albumin, and 1 mM
DTT. After incubation at 30‡C for 15 min, 5 mM MgCl2 and 1 mM
GTP were added. Cell extracts (10 Wl) were added to eIF2^[3H]GDP
complexes and incubated for another 5 min at 30‡C. The [3H]GDP^
GTP exchange reaction was terminated by adding a cold wash bu¡er
containing 50 mM Tris^HCl, pH 7.6, 5 mM MgCl2, 100 mM KCl.
The mixture was ¢ltered through nitrocellulose ¢lters and the activity
of eIF2B was determined by quanti¢cation of the amount of eIF2^
[3H]GDP retained on the ¢lter.
2.8. Statistical analysis
The data are expressed as the mean of at least three independent
experiments performed in duplicateX S.D. The signi¢cance of the ex-
perimental data was validated using Student’s t-test and di¡erences
were considered to be signi¢cant when P6 0.05.
3. Results
3.1. E¡ect of wortmannin on global and Src protein synthesis
Two cell lines were used to study changes in intracellular
signalling induced by RSV transformation: control, non-
transformed hamster ¢broblasts NIL-2 and RSV-transformed
hamster ¢broblasts (H19 cells). As we have previously re-
ported the enhanced overall protein synthesis in H19 cells
was partially decreased by rapamycin [7]. Here we found
that upon wortmannin treatment at nanomolar concentra-
tions, which is known to selectively inhibit PI-3K, global pro-
tein synthesis was inhibited less in the control NIL-2 cells (by
12.3X 0.4%) than in RSV-transformed H19 cells (by
21.5X 0.8%; P6 0.002), indicating a greater requirement for
PI-3K activity in regulation of protein biosynthesis in ¢bro-
blasts transformed by v-src oncogene than in the non-trans-
formed ¢broblasts.
In addition, treatment of cells with 100 nM wortmannin for
20 h resulted in a greater decrease in expression of Src protein
in v-src-transformed H19 cells (by 20X 1.8%) than in the con-
trol NIL-2 cells (by 14X 1.0%; P6 0.002), suggesting an in-
volvement of PI-3K signalling in Src protein synthesis, which
is increased in RSV-transformed cells [6,7].
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3.2. Activity of PI-3K and PKB/Akt
PI-3K is highly activated in RSV-transformed hamster ¢-
broblasts as shown by TLC analysis of the lipid products
generated by phosphotyrosine-associated PI-3K. Almost
four-fold higher amounts of PtdIns were produced in vitro
by PI-3K immunoprecipitated from H19 cells compared to
PtdIns generated by PI-3K immunoprecipitated from NIL-2
cells (Fig. 1). Wortmannin treatment decreased the amounts
of PtdIns produced by PI-3K by 66% in RSV-transformed
cells.
The lipid products of PI-3K are known to bind to the PH
domain of Akt/PKB, and in addition to lipid binding, phos-
phorylation of Ser473 and Thr308 is required for activation of
Akt [16]. In RSV-transformed cells, Ser473 in Akt is highly
phosphorylated as seen in the Western blots of the cell ex-
tracts detected by antibodies that speci¢cally recognized Akt
phosphorylated at Ser473 (Fig. 2). This phosphorylation was
blocked by wortmannin, con¢rming a requirement for PI-3K
for Akt phosphorylation.
To demonstrate activation of Akt, we performed direct ki-
nase assays on Akt present in H19 and NIL-2 cells, using the
synthetic peptide RPRAATF, which is a relatively speci¢c
substrate for Akt [8,17]. As seen in Fig. 3A, phosphorylation
of the peptide was highly increased when it was catalyzed by
Akt present in RSV-transformed cells compared to phosphor-
ylation catalyzed by Akt from the normal cells and was
blocked upon wortmannin treatment, indicating that PI-3K
is involved in the activation of Akt in H19 cells.
Also a GSK-3L fusion protein was used as a substrate to
assay Akt. The data con¢rm that the wortmannin-sensitive
activity of Akt immunoprecipitated from H19 cells is mark-
edly enhanced compared to the activity of Akt immunopreci-
pitated from NIL-2 cells (Fig. 3B).
3.3. Involvement of p70 S6k in PI-3K signalling
Akt may lie upstream of p70 S6k which is thought to be
controlled by both the rapamycin-sensitive signalling pathway
of mTOR and the wortmannin-sensitive PI-3K signalling
pathway. When the state of activation of p70 S6k was ana-
lyzed by means of its migration on SDS^PAGE (increased
phosphorylation and thus activation of p70 S6k is manifested
as lower electrophoretic mobility on SDS^PAGE), four bands
corresponding to p70 S6k could be distinguished on SDS^
PAGE (Fig. 4A). An apparently highly phosphorylated form
of p70 S6k, represented by the most slowly migrating protein
band N, was present in H19 cells, indicating that p70 S6k was
clearly more highly phosphorylated (and therefore activated)
in RSV-transformed H19 cells than in the NIL-2 cells. While
treatment of cells with rapamycin resulted in dephosphoryla-
tion of p70 S6k in both cell lines, NIL-2 and H19 [7], treat-
ment of cells with wortmannin decreased the phosphorylation
of p70 S6k only in NIL-2 cells. Protein band K, the least
phosphorylated form of p70 S6k, was present in wortman-
Fig. 1. Phosphotyrosine-associated PI-3K activity. Chloroform ex-
tracts of the reaction mixtures were subjected to TLC following the
incubation of phosphatidylinositol with [Q-32P]ATP and PI-3K
present in anti-phosphotyrosine immunoprecipitates from control
(NIL-2) and RSV-transformed (H19) cells that were either non-
treated or treated with wortmannin as described in Section 2. The
position of phosphatidylinositol phosphate on the autoradiograph is
indicated.
Fig. 2. Examination of the phosphorylation state of Akt in hamster
¢broblasts. NIL-2 and H19 cells were non-treated or treated with
wortmannin as described in Section 2. Crude cell extracts (20 Wg)
were analyzed by SDS^PAGE followed by Western blotting using:
(A) anti-phospho-Akt(Ser473) antibody and (B) anti-Akt antibody.
C: Densitometric analysis (ImageQuant, Molecular dynamics, Bio-
Rad) of the Western blot of the phosphorylated Akt (A). Data are
expressed as relative phosphorylation of Akt (A) to the signal for
Akt (B).
Fig. 3. PI-3K-dependent activity of Akt/PKB. Control (NIL-2) and
RSV-transformed (H19) cells, which either were non-treated or were
treated with wortmannin, were assayed in vitro for Akt protein ki-
nase activity. A: RPRAATF peptide (150 Wg) was used as a sub-
strate in reaction mixtures containing crude cell extracts (5 Wg) as
described in [8]. Data are the mean of triplicate determination of
three separate experimentsX S.D. B: Autoradiography of SDS^
PAGE (15% gel) of the reaction mixtures containing Akt immuno-
precipitated from NIL-2 and H19 cells, following their incubation in
the presence of [Q-32P]ATP and 1 Wg GSK-3L fusion protein as de-
scribed in Section 2.
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nin-treated control cells, but not in RSV-transformed cells
whether treated with wortmannin or not, demonstrating that
the level of phosphorylation of p70 S6k was unchanged upon
wortmannin treatment of the transformed cells (Fig. 4A).
The translational repressor protein 4E-BP1 is also regulated
by the mTOR pathway. In order to assess the e¡ect of wort-
mannin on its state of phosphorylation, which is increased in
RSV-transformed H19 cells [7], we analyzed trichloroacetic
acid precipitates of the crude extracts of H19 and NIL-2 cells.
As shown in Fig. 4B, three bands corresponding to 4E-BP1
could be distinguished on SDS^PAGE. The most slowly mi-
grating protein band Q, representing an apparently highly
phosphorylated form of 4E-BP1, was present in H19 cells.
Protein band K with the highest electrophoretic mobility, the
least phosphorylated form of 4E-BP1, was present in the con-
trol cells, but not in the transformed cells. As demonstrated,
the level of 4E-BP1 phosphorylation was unchanged upon
wortmannin treatment of both the control and RSV-trans-
formed hamster ¢broblasts.
These ¢ndings show that the increased PI-3K activity in
hamster ¢broblasts induced by v-src transformation is not
involved in the upregulation of the phosphorylation of p70
S6k and 4E-BP1 in the H19 cells.
In agreement with these data phosphorylation of the ribo-
somal S6 protein, the substrate of p70 S6k, was found to be
greatly reduced upon rapamycin treatment in the non-trans-
formed NIL-2 cells and in RSV-transformed H19 cells, while
treatment of the cells with wortmannin resulted in a decrease
in S6 phosphorylation only in the normal NIL-2 cells (by
60X 1.1%) but not in RSV-transformed cells (Fig. 5). This
suggests that RSV transformation of hamster ¢broblasts
changes upstream signalling to p70 S6k to render it indepen-
dent of the PI-3K pathway.
3.4. GSK-3 activity
To examine further PI-3K signalling in hamster ¢broblasts,
we examined the activity of GSK-3, a physiological substrate
for Akt [18]. As shown in Fig. 6, transformation of cells by
the v-src oncogene induced a 43% decrease in the ability of
GSK-3L immunoprecipitates to phosphorylate the peptide
RRAAEELDSRAGS(P)PQ, reproducing a phosphoacceptor
site in the molecule of translation initiation factor eIF2B
[10] that is a GSK-3 substrate. RSV-induced GSK-3 inactiva-
tion was blocked by wortmannin, indicating the upstream
regulation of GSK-3 by PI-3K. Inhibition of PI-3K evidently
alleviated the inhibition of GSK-3. This con¢rms that Akt
activation is dependent on PI-3K signalling in H19 cells.
3.5. eIF2B activity
Phosphorylation of eIF2B by GSK3 results in its inactiva-
tion [14,15]. We therefore examined the GDP/GTP exchange
activity of eIF2B in the non-transformed and RSV-trans-
formed cells and found that the activity of eIF2B increased
in hamster ¢broblasts upon v-src-transformation (Fig. 7).
Wortmannin reduced the enhanced activity of eIF2B in
RSV-transformed H19 cells, and had no e¡ect on the control
NIL-2 cells.
Since the increased eIF2B activity in RSV-transformed cells
could in principle re£ect decreased levels of the physiological
Fig. 5. Analysis of the phosphorylation of S6 ribosomal protein in
NIL-2 and H19 cells. Cells were non-treated or treated with 20 nM
rapamycin (R) or 100 nM wortmannin (W) for 30 min and 10 min
before lysis, respectively, as described in Section 2. A: Crude cell
extracts (20 Wg) of the control NIL-2 cells and RSV-transformed
cells H19 were analyzed by SDS^PAGE followed by Western blot-
ting using anti-phospho-S6 antibody. B: Densitometric analysis (Im-
ageQuant, Molecular dynamics, Bio-Rad) of the Western blot of the
phosphorylated S6 protein (A). Data are expressed as a mean of
four separate experimentsXS.D.
Fig. 6. Activity of GSK-3L in hamster ¢broblasts. In vitro phos-
phorylation of the substrate peptide RRAAEELDSRAGS(P)PQ was
assayed following the immunoprecipitation of GSK-3L from the cell
extracts of the control (NIL-2) and RSV-transformed (H19) cells
with anti-GSK-3L antibody as described in Section 2. The cells were
either non-treated or treated with 100 nM wortmannin as indicated.
Data are the mean of ¢ve separate experimentsX S.D.
Fig. 4. E¡ect of wortmannin on the phosphorylation state of p70
S6k and 4E-BP1 in hamster ¢broblasts. Symbols indicate di¡erent
phosphorylated forms of the analyzed proteins. A: Phosphorylation
of p70 S6k. Crude cell extracts of the control cells NIL-2 and RSV-
transformed cells H19 were analyzed by SDS^PAGE followed by
Western blotting using anti-p70 S6k antibody. Western blot from
the SDS^PA gels of the extracts (15 Wg) of the cells that either were
non-treated or were treated with 100 nM wortmannin as described
in Section 2. B: Phosphorylation of 4E-BP1. Cell extracts of control
NIL-2 and RSV-transformed H19 cells, which either were non-
treated or were treated with 100 nM wortmannin as described in
Section 2, were subjected to precipitation and then analyzed by
SDS^PAGE followed by Western blotting as described previously
[7].
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inhibitor, phosphorylated eIF2K (eIF2KP), [19], the phosphor-
ylation state of initiation factor eIF2K was assessed in NIL-2
and H19 cells that were lysed and analyzed by isoelectric
focusing combined with immunoblotting as in [14]. The pro-
tein bands corresponding to eIF2K and eIF2KP were identi¢ed
by a monoclonal antibody recognizing both forms of eIF2K
(made by the late Dr. Henshaw, Rochester, USA and ob-
tained via Dr. Proud, Dundee, UK). The phosphorylated
form of eIF2K was not detected in NIL-2 or H19 cells, ruling
out this possibility (J. Jir›ic›ka, unpublished).
4. Discussion
The studies described here reveal two important di¡erences
between v-src-transformed and non-transformed cells with re-
spect to the regulation of proteins that modulate protein syn-
thesis and the signalling events that impinge upon them.
Firstly, transformed cells show a high basal activity of PI-
3K. This is re£ected in high basal activity of Akt, decreased
activity of its downstream e¡ector GSK-3 and increased ac-
tivity of the regulatory translation factor eIF2B, which is
phosphorylated and inhibited by GSK-3. Secondly, the high
basal activity of p70 S6k in v-src-transformed cells appears to
be independent of PI-3K, as indicated by its insensitivity to
treatment of cells with wortmannin.
The high level of phosphorylation of 4E-BP1, a second
target of mTOR signalling, also is not a¡ected by wortmannin
in v-src-transformed cells. Nevertheless, the fact that wort-
mannin treatment had no e¡ect on the basal phosphorylation
of 4E-BP1 in the non-transformed NIL-2 cells suggests that
PI-3K is not involved in the control of 4E-BP1 phosphoryla-
tion in hamster ¢broblasts.
The high activity of the PI-3K pathway may contribute to
the dysregulation of cell growth in RSV-transformed cells.
The present data show that eIF2B activity is enhanced in
v-src-transformed cells, presumably due to increased activity
of PI-3K and Akt, and consequent inactivation of GSK-3, a
negative regulator of eIF2B [15,20]. eIF2B is a key regulator
of overall protein synthesis and the increased activity of this
factor in RSV-transformed cells is expected to contribute to
increased activity of its substrate eIF2 and to enhanced rates
of protein synthesis. The PI-3K/Akt signalling pathway has
been shown to block apoptosis and promote cell survival and
proliferation [21]. GSK-3, which is probably a central element
in this survival pathway [22], controls several biosynthetic
pathways and the key proteins of these processes are its sub-
strates. Indeed, it has recently been suggested [23] that regu-
lation of eIF2B via PI-3K/Akt/GSK-3 may play an important
role in cell survival. Thus, the activation of eIF2B in v-src-
transformed cells is expected to exert an antiapoptotic e¡ect.
Previous studies have suggested a model in which PI-3K
and PKB/Akt signal to p70 S6k and 4E-BP1 via mTOR.
One possibility is that mTOR is directly regulated by Akt,
an idea which is supported by the evidence that mTOR is a
direct substrate of Akt [24]. Furthermore, recent data show
that TSC2, which can inhibit mTOR signalling, is inactivated
by Akt [5], providing an additional input from PI-3K/Akt into
regulation of mTOR and its downstream e¡ectors such as p70
S6k and 4E-BP1. Formation of the regulatory complex of p85
subunit of PI-3K with p70 S6k and mTOR [25] also suggests a
role of PI-3K in the activation of p70 S6k in lymphoma cells.
However, other data show that in Drosophila, p70 S6k acti-
vation is independent of PI-3K [26], and Du«fner et al. [27]
have presented data arguing against a role for Akt in the
physiological regulation of p70 S6k.
We have previously shown that phosphorylation and acti-
vation of p70 S6k in both non-transformed NIL-2 cells and
RSV-transformed H19 cells was completely blocked by rapa-
mycin [7]. The observation that the phosphorylation of p70
S6k is sensitive to wortmannin in non-transformed NIL-2
cells, demonstrated in this paper, indicates that p70 S6k is
downstream of PI-3K in normal hamster ¢broblasts. In con-
trast, in RSV-transformed ¢broblasts, wortmannin failed to
decrease the phosphorylation of p70 S6k. These data suggest
that the activation of p70 S6k is not the only or indeed the
major event involved in the upregulation of translation medi-
ated by PI-3K in hamster ¢broblasts transformed by the v-src
oncogene, and that important distinctions exist between the
signalling pathways that modulate protein synthesis in the
non-transformed cells and v-src-transformed cells.
In summary, we have found that at least two signalling
pathways that control mRNA translation are activated by
RSV transformation of hamster ¢broblasts. The ¢rst is the
rapamycin-sensitive mTOR signalling pathway, which regu-
lates the phosphorylation and the activity of ribosomal S6
protein kinase p70 S6k and the phosphorylation of transla-
tional repressor protein 4E-BP1 [7], which is independent of
PI-3K in v-src-transformed cells. The second is a distinct anti-
apoptotic PI-3K/Akt/GSK-3 signalling pathway that increases
the activity of the regulatory initiation factor eIF2B (this
work).
Acknowledgements: We thank Ing. J. Velek (Institute of Organic
Chemistry and Biochemistry, Prague) for RPRAATF peptide. The
excellent technical assistance of Mrs. M. C) echova¤ and Mrs. I. Do-
soudilova¤ is also acknowledged. This work was supported by Grant
312/96/K205 and Grant 301/00/0269 from the Grant Agency of the
Czech Republic and Grant NC/5428-3 from the Ministry of Health of
the Czech Republic.
References
[1] Thomas, G. (2000) Nat. Cell Biol. 2, E71^72.
[2] Gingras, A.C., Raught, B. and Sonenberg, N. (2001) Genes Dev.
15, 807^826.
Fig. 7. GDP/GTP exchange activity of initiation factor eIF2B. The
activity of eIF2B was measured in the extracts from analyzed cells
non-treated or treated with 100 nM wortmannin for 10 min before
lysis. Initiation factor eIF2, the substrate for eIF2B, was puri¢ed
from NIL-2 cells as described in Section 2. Activity of eIF2B was
expressed as a percentage of [3H]GDP released from the eIF2^
[3H]GDP complex. eIF2B activity corresponding to control 2.1 X 0.6
pmol was considered 100%. Data represent the mean of three indi-
vidual experimentsX S.D.
FEBS 27232 7-5-03
M. Vojte›chova¤ et al./FEBS Letters 543 (2003) 81^86 85
[3] Hara, K., Yonezawa, K., Weng, Q.P., Kozlowski, M.T., Belham,
C. and Avruch, J. (1998) J. Biol. Chem. 273, 14484^14494.
[4] Brazil, D.P. and Hemmings, B.A. (2001) Trends Biochem. Sci.
26, 657^664.
[5] McManus, E.J. and Alessi, D.R. (2002) Nat. Cell Biol. 4, E214^
216.
[6] Tuha¤c›kova¤, Z., Vojte›chova¤, M., Hlava¤c›ek, J., Ruzzene, M., So-
vova¤, V. and Pinna, L.A. (2002) Biochem. Biophys. Res. Com-
mun. 290, 790^795.
[7] Tuha¤c›kova¤, Z., Sovova¤, V., S) loncova¤, E. and Proud, C.G. (1999)
Int. J. Cancer 81, 963^969.
[8] Bozinovski, S., Cristiano, B.E., Marmy-Conus, N. and Pearson,
R.B. (2002) Anal. Biochem. 305, 32^39.
[9] Tuha¤c›kova¤, Z. and Kr›iva¤nek, J. (1996) Biochem. Biophys. Res.
Commun. 218, 61^66.
[10] Welsh, G.I., Patel, J.C. and Proud, C.G. (1997) Anal. Biochem.
244, 16^21.
[11] Tuha¤c›kova¤, Z., S) loncova¤, E., Hlava¤c›ek, J., Sovova¤, V. and Ve-
lek, J. (1999) Oncol. Rep. 6, 827^832.
[12] Carpenter, C.L., Duckworth, B.C., Auger, K.R., Cohen, B.,
Scha¡hausen, B.S. and Cantley, L.C. (1990) J. Biol. Chem.
265, 19704^19711.
[13] Old¢eld, S. and Proud, C.G. (1992) Eur. J. Biochem. 208, 73^81.
[14] Welsh, G.I. and Proud, C.G. (1992) Biochem J. 284, 19^23.
[15] Welsh, G.I., Miyamoto, S., Price, N.T., Safer, B. and Proud,
C.G. (1996) J. Biol. Chem. 271, 11410^11413.
[16] Franke, T.F., Yang, S.I., Chan, T.O., Datta, K., Kazlauskas, A.,
Morrison, D.K., Kaplan, D.R. and Tsichlis, P.N. (1995) Cell 81,
727^736.
[17] Alessi, D.R., Caudwell, F.B., Andjelkovic, M., Hemmings, B.A.
and Cohen, P. (1996) FEBS Lett. 399, 333^338.
[18] Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M. and
Hemmings, B.A. (1995) Nature 378, 785^789.
[19] Kimball, S.R., Fabian, J.R., Pavitt, G.D., Hinnebusch, A.G. and
Je¡erson, L.S. (1998) J. Biol. Chem. 273, 12841^12845.
[20] Kleijn, M., Welsh, G.I., Scheper, G.C., Voorma, H.O., Proud,
C.G. and Thomas, A.A.M. (1998) J. Biol. Chem. 273, 5536^5541.
[21] Marte, B.M. and Downward, J. (1997) Trends Biochem. Sci. 22,
355^358.
[22] Pap, M. and Cooper, G.M. (1998) J. Biol. Chem. 273, 19929^
19932.
[23] Pap, M. and Cooper, G.M. (2002) Mol. Cell. Biol. 22, 578^586.
[24] Nave¤, B.T., Ouwens, D.M., Withers, D.J., Alessi, D.R. and
Shepherd, P.R. (1999) Biochem. J. 344, 427^431.
[25] Gonza¤lez-Carc|¤a, A., Garrido, E., Herna¤ndez, C., Alvarez, B.,
Jime¤nez, C., Cantrell, D.A., Pullen, N. and Carrera, A.C.
(2002) J. Biol. Chem. 277, 1500^1508.
[26] Radimerski, T., Montagne, J., Rintelen, F., Stocker, H., van der
Kaay, J., Downes, C.P., Hafen, E. and Thomas, G. (2002) Nat.
Cell Biol. 4, 251^255.
[27] Du«fner, A., Andjelkovic, M., Burgering, B.M., Hemmings, B.A.
and Thomas, G. (1999) Mol. Cell. Biol. 19, 4525^4534.
FEBS 27232 7-5-03
M. Vojte›chova¤ et al./FEBS Letters 543 (2003) 81^8686
